Patented Medicine Sales Reach $24.4 Billion in Canada

Federal Health Minister tabled the 2025 Annual Report of the Patented Medicine Prices Review Board in Parliament.

Updated on Nov. 20, 2026 in Healthcare

Bold vector editorial illustration of a tall stack of cream and teal capsule forms beside a dark slate block on a pale field, evoking measured pharmaceutical spending.
Canadians spent $24.4 billion on patented medicines in 2025, a 10.6% increase that accounted for 48% of all medicine sales, according to the PMPRB's annual report. AI Illustration. Upload story photo >

Live Poll

Do you think Canadians are paying fair prices for prescription medicines?

Sales of patented medicines in Canada totaled $24.4 billion in 2025, a 10.6% increase over the prior year. The figures, detailed in the Patented Medicine Prices Review Board's annual report, show patented medicines accounted for 48% of all medicine sales in the country.

Why it matters

The PMPRB reviews patented medicine prices to protect Canadians from patent abuse related to excessive prices. The report gives Parliament and the public a yearly view of how pricing and spending on new medicines are trending.

Rights holders reported $1.73 billion in R&D expenditures in 2025 against $24.4 billion in patented medicine sales, an average sales-to-R&D ratio of 4.9%. Canada represented 2.1% of worldwide pharmaceutical sales and ranks as the eighth largest national pharmaceutical market.

The players

Patented Medicine Prices Review Board

The PMPRB is a federal quasi-judicial body that regulates the prices of patented medicines sold in Canada and publishes annual reports on pricing and sales trends.

The details

The report, tabled with the Clerks of the Senate and the House of Commons, reviews trends in the prices and sales of patented medicines in Canada. It also reports that 1,086 patented medicines for human use and 82 new dosage forms and strengths were reported to the PMPRB in 2025.

Timeline

  1. 2025: Period covered by the reported sales, R&D spending and price data.

  2. November 20, 2026: Minister tabled the 2025 Annual Report in Parliament.

Market Landscape

The PMPRB's annual reporting under the Patent Act tracks how Canada's pricing of patented medicines compares with peer countries, with Canadian list prices ranking third highest among PMPRB11 nations. The 2025 figures show that patented medicines now account for nearly half of all medicine sales in Canada.

Patients and families who rely on patented medicines are affected by the prices and sales trends the report documents, which shape what drugs cost and which are available. The findings give Canadians a benchmark for judging whether medicine prices are reasonable compared with other countries.

The takeaway

Canadian list prices for patented medicines rank among the highest in peer countries, so the figures are a useful benchmark when weighing drug costs. Tracking the annual PMPRB reports can help readers follow how those prices change over time.

Further reading

Explore more on Healthcare industry coverage for context on drug pricing and pharmaceutical markets.

Source note: This article includes information reported by Brantford Expositor.

Live Poll

Do you think Canadians are paying fair prices for prescription medicines?